Adverum Biotechnologies, Inc. (ADVM) |
|
0.8091 0.051 (6.78%)
|
03-27 16:00 |
|
Open: |
0.7577 |
Pre. Close: |
0.7577 |
|
High:
|
0.8132 |
Low:
|
0.7577 |
|
Volume:
|
317,636 |
Market Cap:
|
81(M) |
|
|
|
Technical analysis |
as of: 2023-03-27 4:17:08 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 1 One year: 1.17 |
| Support: |
Support1: 0.71 Support2: 0.62 |
| Resistance: |
Resistance1: 0.86 Resistance2: 1 |
| Pivot: |
0.79 |
| Moving Average: |
MA(5): 0.77 MA(20): 0.78
MA(100): 0.69  MA(250): 0.96 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 34.4 %D(3): 32.3 |
| RSI: |
RSI(14): 58.5 |
| 52-week: |
High: 1.82 Low: 0.53 |
| Average Vol(K): |
3-Month: 439 (K) 10-Days: 821 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ADVM ] has closed below upper band by 35.4%. Bollinger Bands are 26.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.76 - 0.76 |
0.76 - 0.77 |
|
Low:
|
0.72 - 0.72 |
0.72 - 0.73 |
|
Close:
|
0.75 - 0.76 |
0.76 - 0.77 |
|
Company Description |
|
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. |
Headline News |
Fri, 24 Mar 2023
Adverum Biotechnologies Inc : A loss of 36 cents per ... - Kalkine Media
Fri, 24 Mar 2023
Metacrine Inc expected to post a loss of 14 cents a share - Earnings ... - Kalkine Media
Thu, 23 Mar 2023
DelveInsight Highlights Major Advances, Transformative Therapies ... - Medgadget
Thu, 09 Mar 2023
Adverum Biotechnologies Inc (ADVM) Stock: What Does the Chart ... - InvestorsObserver
Wed, 08 Mar 2023
Diabetic Retinopathy Pipeline Research Report 2022: Featuring ... - Business Wire
Fri, 24 Feb 2023
We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
100 (M) |
| Shares Float |
84 (M) |
|
% Held by Insiders
|
3.6 (%) |
|
% Held by Institutions
|
58.3 (%) |
|
Shares Short
|
1,560 (K) |
|
Shares Short P.Month
|
1,570 (K) |
Stock Financials |
|
EPS
|
-1.49 |
|
EPS Est Next Qtl
|
-0.32 |
|
EPS Est This Year
|
-1.26 |
|
EPS Est Next Year
|
-1.31 |
|
Book Value (p.s.)
|
2.08 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-23 |
|
Return on Equity (ttm)
|
-56.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.82 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.46 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-115 (M) |
|
Levered Free Cash Flow
|
-84 (M) |
Stock Valuations |
|
PE Ratio
|
-0.55 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.38 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.7 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
